

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
25 May 2023 (25.05.2023)



(10) International Publication Number
WO 2023/088221 A1

(51) International Patent Classification:

C07K 16/28 (2006.01) A61K 39/395 (2006.01)
A61P 35/00 (2006.01)

(21) International Application Number:

PCT/CN2022/131820

(22) International Filing Date:

15 November 2022 (15.11.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/CN2021/130995

16 November 2021 (16.11.2021) CN

PCT/CN2022/125150

13 October 2022 (13.10.2022) CN

(71) Applicants: SUZHOU TRANSCENTA THERAPEUTICS CO., LTD. [CN/CN]; B6-501, 218 Xinghu Street, Suzhou, Jiangsu 215123 (CN). TRANSCENTA HOLDING LIMITED; 190 Elgin Avenue, George Town, Grand Cayman KY1-9008 (KY). TRANSCENTA THERAPEUTICS, INC. [US/US]; Three Independence Way, Suite 114, Princeton, NJ 08540 (US).

(72) Inventors: QIAN, Xueming; B6-501, 218 Xinghu Street, Suzhou, Jiangsu 215123 (CN). YAO, Xinlai; B6-501, 218 Xinghu Street, Suzhou, Jiangsu 215123 (CN). GUO, Huanhuan; B6-501, 218 Xinghu Street, Suzhou, Jiangsu 215123 (CN). TENG, Fei; B6-501, 218 Xinghu Street, Suzhou, Jiangsu 215123 (CN). YI, Wei; B6-501, 218 Xinghu Street, Suzhou, Jiangsu 215123 (CN).

(74) Agent: JUN HE LAW OFFICES; 20/F, China Resources Building 8 Jianguomenbei Avenue, Beijing 100005 (CN).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,

TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

WO 2023/088221 A1

(54) Title: COMBINATION THERAPY OF CLAUDIN 18.2 ANTAGONIST AND PD-1/PD-L1 AXIS INHIBITOR

(57) Abstract: Provided are combination therapies of a CLDN 18.2 antagonist and a PD-1/PD-L1 axis inhibitor for subjects having expression of CLDN 18.2 and having low or no expression of PD-L1 in a disease tissue (e.g., tumor tissue) obtained from the subject.